Supriya Lifescience Ltd. announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company delivered a 11.2% year-over-year growth in Revenue for Q3 FY26, reaching Rs 206.44 crore. Profit After Tax (PAT) also increased to Rs 49.68 crore. Management highlighted consistent execution, strong global demand, and operational improvements driven by capacity utilization recovery.
Supriya Lifescience Q3 FY26 Financial Performance
Supriya Lifescience Ltd. released its unaudited consolidated financial highlights for the third quarter of the financial year 2026 (Q3 FY26), reporting robust performance across key metrics compared to Q3 FY25.
Key Consolidated Financial Highlights (Q3)
| Particulars | Q3 FY26 (Rs Cr) | Q3 FY25 (Rs Cr) |
|---|---|---|
| Revenues | 206.44 | 185.65 |
| EBITDA | 72.08 | 65.96 |
| EBITDA Margin | 34.9% | 35.5% |
| PAT | 49.68 | 46.78 |
| PAT Margin | 24.1% | 25.2% |
| Quarterly EPS (Rs) | 6.2 | 5.8 |
The company achieved a 11.2 % year-over-year growth in Revenue to Rs 206.44 crore in Q3 FY26. EBITDA for the quarter stood at Rs 72.08 crore, resulting in an EBITDA margin of 34.9%. Profit After Tax (PAT) saw an increase to Rs 49.68 crore from Rs 46.78 crore in the previous corresponding period.
Nine Month (9M FY26) Segment Growth Drivers
Analysis across the nine-month period revealed significant shifts in the contribution of therapeutic segments. The anesthetic segment emerged as the primary growth driver, contributing 54% of total revenues, up from 48% in 9M FY25. Additionally, the vitamins segment improved its contribution from 11% to 12%.
Geographical Performance and Capacity Utilization
Growth for the period was notably driven by the Latin American market, whose contribution grew to 24% from 21% in the business mix. North America’s share also increased to 6%. However, Europe remains the largest market, accounting for 36% of Q3 FY26 business revenues, followed closely by Asia at 32%.
Capacity utilization saw marked improvement, recovering from 70% in FY25 to 76% in 9MFY26. This recovery was supported by the ramp-up of Module E at the Lote Parshuram facility, which is expected to enhance efficiency and supply reliability. The company is also preparing for the commercial launch of its Ambernath formulation facility in Q4 FY26.
Management Commentary
Mr. Satish Wagh, Executive Chairman and Whole Time Director, stated that the performance reflects consistent execution and sustained profitability, supported by steady global demand. Exports continued to be a strong focus, accounting for approximately 82% of revenues in Q3. The company remains confident in driving stronger growth through backward integration and new product introductions as it deepens its presence in regulated markets.
Source: BSE
